Bio-Techne Corporation Grants Restricted Stock Unit Award to CFO

Bio-Techne Corporation (NASDAQ: TECH) made an official announcement in an 8-K filing with the Securities and Exchange Commission on October 30, 2024, revealing that the Compensation Committee of the Board of Directors has granted a one-time restricted stock unit award to James Hippel, the company’s Executive Vice President and Chief Financial Officer.

The award consists of 34,634 shares and was issued under the company’s 2020 Equity Incentive Plan. This restricted stock unit will vest in equal installments over the course of the first three anniversaries of the grant date, contingent upon Mr. Hippel’s continuous employment with Bio-Techne, and in accordance with the terms of the Plan and the associated award agreement.

The decision to grant this restricted stock unit award to Mr. Hippel was made with the intention of retaining his services, following a stock plan administrative error that led to the forfeiture of stock options due to a misrecorded expiration date.

Additionally, the filing noted that the requisite financial statements and exhibits are detailed under Item 9.01 of the Form 8-K filing.

The document was signed by Shane V. Bohnen, Senior Vice President, General Counsel, and Corporate Secretary of Bio-Techne Corporation, on behalf of the company on November 5, 2024.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Bio-Techne’s 8K filing here.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.